Literature DB >> 16177847

Latent arterial hypertension in apparently lone atrial fibrillation.

Demosthenes G Katritsis1, Ioannis K Toumpoulis, Eleftherios Giazitzoglou, Socrates Korovesis, Ilias Karabinos, George Paxinos, Constantinos Zambartas, Constantine E Anagnostopoulos.   

Abstract

INTRODUCTION: Longitudinal studies on lone AF are rare and the incidence of hypertension in this population unknown. This study aimed at investigating the incidence of arterial hypertension in patients with apparently lone atrial fibrillation (AF). METHODS AND
RESULTS: Out of 292 consecutive patients presented with permanent or paroxysmal AF, 32 patients were diagnosed as having lone AF according to strict criteria. Three patients were subjected to ablation of the ligament of Marshall, 14 patients to pulmonary vein isolation, and the remainder were treated with beta blockade. Patients were followed-up for a 1-3 year period. During follow-up, 14 patients were diagnosed as having arterial hypertension. Thirteen of them had recurrent AF despite ligament of Marshall ablation (1 patient), pulmonary vein isolation (4 patients) and beta blockade (8 patients). Cox regression analysis revealed that the only significant predictor of development of hypertension was complete or partial response to antiarrhythmic therapy (beta=3.82, S.E.=1.22, exp(b)=45.63, 95% C.I.=4.17-499.2, p=0.001), independent of age (beta=-0.01, p=0.74), sex (beta=-0.91, p=0.28), left ventricular ejection fraction (beta=0.06, p=0.52), left atrial size (beta=0.58, p=0.7) and kind of antiarrhythmic therapy (ablation or drug therapy) (beta=1.36, p=0.09). In patients with lone AF that did not respond at all to antiarrhythmic therapy, there was a 45.6 times higher risk of diagnosing hypertension during the next 3 years as compared to responders.
CONCLUSION: Approximately 44% of patients with an initial diagnosis of lone AF may represent occult cases of arterial hypertension. In these patients hypertension may affect AF recurrence and treatment outcomes, regardless of the mode of antiarrhythmic therapy used.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177847     DOI: 10.1007/s10840-005-2360-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  20 in total

1.  Lone atrial fibrillation: epidemiology and natural history.

Authors:  B J Gersh; A Solomon
Journal:  Am Heart J       Date:  1999-04       Impact factor: 4.749

2.  Identification and catheter ablation of extracardiac and intracardiac components of ligament of Marshall tissue for treatment of paroxysmal atrial fibrillation.

Authors:  D Katritsis; J P Ioannidis; C E Anagnostopoulos; G E Sarris; E Giazitzoglou; S Korovesis; A J Camm
Journal:  J Cardiovasc Electrophysiol       Date:  2001-07

3.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

Authors:  O D Pedersen; H Bagger; L Kober; C Torp-Pedersen
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

4.  Long-lasting sport practice and lone atrial fibrillation.

Authors:  L Mont; A Sambola; J Brugada; M Vacca; J Marrugat; R Elosua; C Paré; M Azqueta; G Sanz
Journal:  Eur Heart J       Date:  2002-03       Impact factor: 29.983

5.  Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

6.  The natural history of lone atrial fibrillation. A population-based study over three decades.

Authors:  S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

7.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study.

Authors:  F N Brand; R D Abbott; W B Kannel; P A Wolf
Journal:  JAMA       Date:  1985-12-27       Impact factor: 56.272

8.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

Review 9.  Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target.

Authors:  Jeff S Healey; Stuart J Connolly
Journal:  Am J Cardiol       Date:  2003-05-22       Impact factor: 2.778

10.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

View more
  9 in total

1.  A novel management program for hypertension.

Authors:  Chun-Song Hu; Ya-Ling Han; Jun-Bo Ge; Qing-Hua Wu; Yan-Na Liu; Chang-Sheng Ma; Tengiz Tkebuchava; Da-Yi Hu
Journal:  Cardiovasc Diagn Ther       Date:  2015-08

Review 2.  Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy.

Authors:  Babar Parvez; Dawood Darbar
Journal:  J Atr Fibrillation       Date:  2010-06-01

Review 3.  The Role Of Renin Angiotensin System In Atrial Fibrillation.

Authors:  Girish M Nair; Pablo B Nery; Calum J Redpath; David H Birnie
Journal:  J Atr Fibrillation       Date:  2014-04-30

4.  Lone Atrial Fibrillation: Risk Factors, Triggers And Ablation Techniques.

Authors:  Mindy Vroomen; Laurent Pison
Journal:  J Atr Fibrillation       Date:  2015-06-30

5.  Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis.

Authors:  Mariëlle Kloosterman; Jonas Oldgren; David Conen; Jorge A Wong; Stuart J Connolly; Alvaro Avezum; Salim Yusuf; Michael D Ezekowitz; Lars Wallentin; Marie Ntep-Gweth; Philip Joseph; Tyler W Barrett; Supachai Tanosmsup; William F McIntyre; Shun Fu Lee; Ratika Parkash; Guy Amit; Alex Grinvalds; Isabelle C Van Gelder; Jeff S Healey
Journal:  Europace       Date:  2020-06-01       Impact factor: 5.214

6.  Concealed Coronary Atherosclerosis In Idiopathic Paroxysmal Atrial Fibrillation is Associated with Imminent Cardiovascular Diseases.

Authors:  Eamp Dudink; B Weijs; Jglm Luermans; Fecm Peeters; S Altintas; K Vernooy; Lafg Pison; R J Haest; J A Kragten; Bljh Kietselaer; J E Wildberger; Hjgm Crijns
Journal:  J Atr Fibrillation       Date:  2020-12-31

7.  Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study.

Authors:  B Weijs; E A M P Dudink; C B de Vos; I Limantoro; R G Tieleman; R Pisters; E C Cheriex; J G L M Luermans; H J G M Crijns
Journal:  Neth Heart J       Date:  2019-10       Impact factor: 2.380

8.  Relation of Biomarkers of Inflammation and Oxidative Stress with Hypertension Occurrence in Lone Atrial Fibrillation.

Authors:  Marija M Polovina; Miodrag C Ostojic; Tatjana S Potpara
Journal:  Mediators Inflamm       Date:  2015-07-01       Impact factor: 4.711

9.  Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study.

Authors:  Naiara Calvo; Pablo Ramos; Silvia Montserrat; Eduard Guasch; Blanca Coll-Vinent; Mònica Domenech; Felipe Bisbal; Sara Hevia; Silvia Vidorreta; Roger Borras; Carles Falces; Cristina Embid; Josep Maria Montserrat; Antonio Berruezo; Antonio Coca; Marta Sitges; Josep Brugada; Lluís Mont
Journal:  Europace       Date:  2015-09-01       Impact factor: 5.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.